Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Medicure Inc V.MPH

Alternate Symbol(s):  MCUJF

Medicure Inc. is a Canada-based pharmaceutical company. The Company is focused on the development and commercialization of therapies for the United States cardiovascular market. The focus of the Company is the marketing and distribution of AGGRASTAT (tirofiban hydrochloride) injection and ZYPITAMAG (pitavastatin) tablets in the United States, where they are sold through the Company’s United... see more

TSXV:MPH - Post Discussion

Medicure Inc > Sell the Company
View:
Post by carrot50 on May 14, 2020 12:26pm

Sell the Company

They need to sell this thing to another pharma company who knows how to run a business..

No REDS sale - Zero in first quarter. What a bust and waste of millions.

They have 20 sales people on staff and are on track to have under $20 million is sales this year.
Thats under a million dollars each.
They should be at $4 million each.

Listened to the CC and boy there sure seems to be a lack of enthusiasm

Probably at he bottom at $1.10

But second quarter better improve of were going back to a penny stock.
Be the first to comment on this post
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities